CDK2 and glioblastoma: Therefore, we hypothesized that TTFields could reduce the expression of CDK2-AS1, which further decreased the expression of CDK2 via mitigating CDK2 mRNA stability and resulted in GBM cell cycle arrest (Fig. 8G).